UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
GoodRx Holdings, Inc. Class A
GoodRx Holdings, Inc. Class A GDRX | 0.00 |
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:
GDRX) with a Neutral and raises the price target from $2.5 to $3.75.
